Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

CareDx Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

John Hanna

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	1.1yrs
Yönetim Kurulu ortalama görev süresi	9.6yrs

Son yönetim güncellemeleri

Recent updates

CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics

Sep 29

CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 34% But Its Business Prospects Need A Lift Too

Aug 01

CareDx: Benefiting From Some Certainty

Jul 15

Why Investors Shouldn't Be Surprised By CareDx, Inc's (NASDAQ:CDNA) 28% Share Price Plunge

Apr 27

CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 40% But Its Business Prospects Need A Lift Too

Mar 02

CareDx, Inc's (NASDAQ:CDNA) Shares Bounce 26% But Its Business Still Trails The Industry

Dec 27

CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Dec 27

CEO

John Hanna (44 yo)

less than a year

Görev süresi

Mr. John Walter Hanna, Jr. is President, CEO & Director of CareDx, Inc since April 15, 2024. He served as General Manager of Endocrinology, Breast Cancer and Lymphoma at Veracyte, Inc. since January 1, 202...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Abhishek Jain	CFO & Principal Accounting Officer	2.4yrs	US$3.09m	0.076% $ 1.2m
Peter Maag	Executive Director	2.9yrs	US$354.93k	0.51% $ 8.3m
John Hanna	President	less than a year	Veri yok	Veri yok
Keith Kennedy	Chief Operating Officer	less than a year	Veri yok	Veri yok
Robert Woodward	Chief Scientific Officer	1.1yrs	Veri yok	Veri yok
Jeffrey Novack	General Counsel & Secretary	less than a year	Veri yok	0.23% $ 3.7m
Stacey Follon	Senior VP & Head of Human Resources	1.8yrs	Veri yok	Veri yok
Kashif Rathore	Head of Software Engineering	no data	Veri yok	Veri yok

1.1yrs

Ortalama Görev Süresi

48yo

Ortalama Yaş

Deneyimli Yönetim: CDNA 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Peter Maag	Executive Director	11.9yrs	US$354.93k	0.51% $ 8.3m
John Hanna	President	less than a year	Veri yok	Veri yok
Fred Cohen	Independent Director	21.8yrs	US$355.87k	0.22% $ 3.5m
Michael Goldberg	Independent Chairman	12.9yrs	US$456.03k	0.21% $ 3.4m
Christine Cournoyer	Independent Director	5.1yrs	US$384.45k	0.046% $ 752.0k
William Hagstrom	Independent Director	9.6yrs	US$360.87k	0.047% $ 759.3k
Jeffrey Bluestone	Member of Advisory Board	no data	Veri yok	Veri yok
Mary Crow	Member of Advisory Board	no data	Veri yok	Veri yok
Robert Tibshirani	Member of Advisory Board	no data	Veri yok	Veri yok
George Bickerstaff	Independent Director	10.5yrs	US$368.74k	0.16% $ 2.7m
R. Riggsbee	Independent Director	less than a year	Veri yok	Veri yok
Arthur Torres	Independent Director	3.1yrs	US$353.74k	0.013% $ 215.3k

9.6yrs

Ortalama Görev Süresi

67.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CDNA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.6 yıldır).

CareDx Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

CareDx, Inc Appoints Keith Kennedy as Chief Operating Officer

Executive Director exercised options to buy US$123k worth of stock.

CareDx, Inc, Annual General Meeting, Jun 13, 2024

CareDx, Inc Appoints John W. Hanna as Chief Executive Officer

CareDx, Inc Appoints Bryan Riggsbee to Its Board of Directors

CareDx, Inc Announces Resignation of Reginald Seeto as Chief Executive Officer

Recent updates

CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics

CareDx, Inc Appoints Keith Kennedy as Chief Operating Officer

CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 34% But Its Business Prospects Need A Lift Too

CareDx, Inc Revises Earnings Guidance for the Full Year 2024

CareDx, Inc to Report Q2, 2024 Results on Jul 31, 2024

CareDx: Benefiting From Some Certainty

CareDx, Inc Announces New Data to Be Presented At the 2024 American Transplant Congress

Study Shows CareDx, Inc.’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies

Price target increased by 11% to US$14.40

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Executive Director exercised options to buy US$123k worth of stock.

CareDx, Inc, Annual General Meeting, Jun 13, 2024

Why Investors Shouldn't Be Surprised By CareDx, Inc's (NASDAQ:CDNA) 28% Share Price Plunge

CareDx, Inc Appoints John W. Hanna as Chief Executive Officer

CareDx, Inc Appoints Bryan Riggsbee to Its Board of Directors

CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 40% But Its Business Prospects Need A Lift Too

Full year 2023 earnings: EPS misses analyst expectations

CareDx, Inc Provides Revenue Guidance for the Full Year of 2024

CareDx, Inc to Report Q4, 2023 Results on Feb 28, 2024

Jury Rules in Favor of Natera, Inc in Patent Infringement Lawsuit Against CareDx, Inc

CareDx, Inc Provides Earnings Guidance for Fourth Quarter Ended December 31, 2023

Price target increased by 11% to US$11.80

CareDx, Inc's (NASDAQ:CDNA) Shares Bounce 26% But Its Business Still Trails The Industry

CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents

CareDx, Inc to Report Q3, 2023 Results on Nov 08, 2023

CareDx, Inc Announces Resignation of Reginald Seeto as Chief Executive Officer

CareDx Issues Statement on Supreme Court Decision Regarding Stanford-Licensed Patents

CareDx, Inc Announces Executive Changes

SEC Concludes Investigation as to CareDx and Does Not Intend to Recommend an Enforcement Action

Price target decreased by 16% to US$10.80

Consensus EPS estimates fall by 14%

Independent Director exercised options to buy US$173k worth of stock.

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

CareDx, Inc. Provides Revenue Guidance for the Full Year 2023

CareDx, Inc to Report Q2, 2023 Results on Aug 08, 2023

CareDx, Inc. Announces Medicare Coverage for HeartCare

Price target increased by 26% to US$12.60

CareDx, Inc (NasdaqGM:CDNA) acquired MediGO, Inc.

CareDx’s AlloSure Lung dd-cfDNA Testing Service Receives Medicare Coverage for Lung Transplant Rejection Monitoring

New minor risk - Share price stability

President notifies of intention to sell stock

Benign Growth For CareDx, Inc (NASDAQ:CDNA) Underpins Its Share Price

Consensus revenue estimates fall by 13%

Analyst Forecasts Just Became More Bearish On CareDx, Inc (NASDAQ:CDNA)

First quarter 2023 earnings: EPS and revenues miss analyst expectations

CareDx, Inc to Report Q1, 2023 Results on May 10, 2023

Consensus EPS estimates fall by 10%

Price target decreased by 22% to US$20.40

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

CareDx, Inc. Showcases Latest Advancements in Cellular Transplant and Therapy Including Specialized Digital Health Solutions At the 2023 Tandem Meetings

Executive Director notifies of intention to sell stock

Executive Director notifies of intention to sell stock

Price target decreased by 7.6% to US$26.17

CareDx, Inc Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

President notifies of intention to sell stock

Executive Officer notifies of intention to sell stock

CareDx, Inc (NasdaqGM:CDNA) announces an Equity Buyback for $50 million worth of its shares.

CareDx, Inc Announces the Results of A New Study Published in Transplantation Direct

CareDx, Inc Announces Resignation of Ralph Snyderman as Director, Effective from December 31, 2022

Price target decreased to US$30.00

Third quarter 2022 earnings released: US$0.32 loss per share (vs US$0.23 loss in 3Q 2021)

Caredx, Inc., Revises Revenue Guidance for the Full Year 2022

Independent Longitudinal Study Finds Caredx’S Allosure Detects Early Signs of Rejection in Pediatric Kidney Transplant Patients

CareDx, Inc to Report Q3, 2022 Results on Nov 03, 2022

CareDx: Shaking Off First-Mover Disadvantage

Caredx, Inc Announces Transplant Patients Experience Less Pain and Fewer Adverse Events with Caredx Non-Invasive Testing Solutions

CareDx, Inc Announces Executive Changes